• #LGM Pharma is a Fidaxomicin CAS# 873857-62-6 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 873857-62-6
  • AHFC code: 8:12.12.92
  • Synonyms: BRN 5228707, Clostomicin B1, Dificid, Fidaxomicin, Lipiarmicin, Lipiarmycin, Lipiarmycin A 3, OPT 80, OPT-80, PAR 01, PAR 101, PAR-101, R-Tiacumicin B, Tiacumicin B, UNII-Z5N076G8YQ
  • ATC Code: A07AA12
  • Chemical Formula: C52-H74-Cl2-O18
  • Molecular Weight: 1058.0446
  • Assay/Purity: Typically NLT 98%
  • DrugBank:
  • SMILES: CC[C,H]1C=C(C)[C,,H](O)CC=CC=C(CO[C,,H]2O[C,H](C)[C,,H](OC(=O)C3=C(CC)C(Cl)=C(O)C(Cl)=C3O)[C,H](O)[C,,H]2OC)C(=O)OC(CC=C(/C)C=C(C)[C,,H]1O[C,,H]1OC(C)(C)[C,,H](OC(=O)C(C)C)[C,H](O)[C,,H]1O)[C,,H](C)O
  • InChl:
  • PubChem:
  • IUPAC:

Additional Details

Indication:
Treatment of Clostridium difficile-associated diarrhea
Pharmacodynamics:
The minimum inhibitory concentration for 90% of organisms for fidaxomicin against C. difficile is 0.9978 to 2 µg/mL.
Mode of Action:
Fidaxomicin is a bactericidal-type antibiotic that inhibits RNA polymerase sigma subunit. RNA polymerase is responsible for transcription in the bacteria therefore fidaxomicin will inhibit protein synthesis. As a result, apoptosis is triggered in susceptible organisms such as C. difficile.
Metabolism:
Fidaxomicin is hydrolyzed by gastric acid or intestinal microsomes into a less active metabolite (OP-1118). The cytochrome enzyme system are not involved in the metabolism of fidaxomicin.
Toxicity:
General Reference:
Artsimovitch I, Seddon J, Sears P: Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis. Clin Infect Dis. 2012 Aug;55 Suppl 2:S127-31. doi: 10.1093/cid/cis358. PubmedCrawford T, Huesgen E, Danziger L: Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection. Am J Health Syst Pharm. 2012 Jun 1;69(11):933-43. doi: 10.2146/ajhp110371. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos